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Abstract 
Approximately 15% of pregnant women vape electronic cigarettes (e-cigarettes), exposing the 
foetus to a range of toxic compounds, including nicotine and by-products of e-cigarette liquid 
(e-liquid) pyrolysis. Due to the recent emergence of these products, health impacts mainly 
focus on immediate users, while less emphasis is placed on in-utero exposure. Therefore, the 
aim of this study was to understand the impact of continuous intrauterine e-cigarette vapour (e-
vapour) exposure, with and without nicotine, on liver metabolic markers in male offspring. E-
vapour was generated using an e-cigarette filled with commercial tobacco flavoured e-liquid 
(18mg/mL or 0mg/mL nicotine). Female Balb/c mice were exposed to e-vapour for 6 weeks 
before mating, through gestation and lactation, without direct exposure to the offspring. Livers 
and plasma from dams and male offspring (13 weeks old) were examined. Maternal e-vapour 
exposure caused insulin resistance in the dams and impaired glucose tolerance in the offspring, 
independent of nicotine. Exposure to nicotine-free e-vapour increased liver damage in the dams 
and offspring associated with nutrient metabolic changes, which were somehow not observed 
in the offspring exposed to nicotine-free e-vapour. Maternal exposure to e-vapour with nicotine 
did not cause liver damage but increased liver triglyceride accumulation in the offspring. 
Therefore, chemicals from the heated humectant may contribute to liver and metabolic 
disorders; whereas nicotine may partly protect the offspring from the adverse hepatic and 
metabolic impacts of maternal e-vaping during pregnancy.  
 
Introduction 
Electronic cigarettes (e-cigarettes) are marketed as a smoking cessation aid, with claims of 
safety over tobacco cigarettes and their popularity is derived from safety perceptions, current 
trends, and reduced costs compared to tobacco cigarette smoking 1. Over the past decade, e-
cigarette vaping (vaping) has become increasingly popular, even amongst individuals without 
prior tobacco smoking history. Despite recent reports of pulmonary illness in the US, vaping 
remains a prevalent recreational addiction 2, especially among young adults, with an estimated 
3.5 million US middle and high school students using them in 2018 3. Given the rates of 
unplanned pregnancies and perceptions of safety, this may inadvertently increase the number 
of individuals exposed to e-vapour in-utero.  
E-cigarette liquid (e-liquid) is composed of nicotine and flavouring compounds suspended in 
a humectant (normally propylene glycol and/or glycerine) 4. Heating this liquid produces an 
aerosol (e-vapour) which is toxic, oxidative, and induces inflammation 1. In previous studies, 
intrauterine nicotine administration altered birth weight along with postnatal lung and brain 
development, leading to respiratory and neurological disorders 5. Apart from nicotine, e-vapour 
also contains a complex and diverse mixture of particulate matter, volatile organic compounds, 
and heavy metals, which can have potential health consequences when inhaled 2. Previously, 
we have shown that intrauterine e-vapour exposure increased inflammatory responses in 
multiple organs, including the lungs 6, brain 7, 8, and kidneys 9, associated with mitochondrial 
alterations and oxidative stress 9, which are mostly nicotine independent. However, the impacts 
of intrauterine e-vapour exposure on liver health and nutrient metabolism are unknown.  
In mouse models of maternal smoking during pregnancy, intrauterine tobacco smoke exposure 
impairs foetal development and increases mitochondrial-derived oxidative stress in the liver in 
adulthood 10. This is closely related to increased inflammation, fatty liver changes, and 
systemic lipid and glucose metabolic disorders in the offspring with no sexual difference 10,11. 
Given the inflammatory response and oxidative stress induced by maternal e-vapour exposure 
in the lungs, brain, and kidneys 6-9, we hypothesised that long-term maternal e-vapour exposure 
might lead to similar disorders in the liver, resulting in glucose and lipid metabolic changes in 
both the dams and their offspring. Therefore, the aims of this study were to investigate the 
impacts of maternal e-vapour exposure from prior to gestation and during pregnancy on hepatic 
metabolic markers, oxidative stress, inflammation and mitochondrial health in both the mothers 
and their male offspring. Only male offspring were examined due to similar metabolic responses 
to the impacts of maternal smoking between male and female offspring.  
Methods 
Animals 
The animal experiments were approved by the Animal Care and Ethics Committee of the 
University of Technology Sydney (ETH15-0025) and performed according to the Australian 
National Health & Medical Research Council Guide for the Care and Use of Laboratory 
Animals. Virgin female Balb/c mice (7 weeks old, Animal Resource Centre, WA, Australia) 
had ad libitum access to standard laboratory chow and water while housed at 20±2 °C and 
maintained on a 12-h light, 12-h dark cycle (lights on at 06:00 h). Female breeders were 
acclimatised for a week prior to the exposure treatments detailed below.  
 
Female breeders were exposed to room air (Sham, n=8), e-vapour generated from e-liquid 
containing 18mg/mL nicotine (E-cig18, n=8), or e-vapour from nicotine-free e-liquid (E-cig0, 
n=8) twice daily for 6 weeks prior to mating and throughout gestation and lactation, as 
previously described 9. E-vapour was generated by a human-use e-cigarette device 
(KangerTech NEBOX, 30 Watts, 0.5 Ohms, KangerTech, Shenzen, China) from commercial 
e-liquid (50% propylene glycol/50% vegetable glycerine, tobacco flavour, Vaper Empire, VIC, 
Australia) as we have previously published in the same model 6. The nicotine dose in the E-
cig18 groups represents mothers who are light smokers 6. Dams were removed from their home 
cages during exposure, while the male breeders and pups were not exposed. Male offspring 
were weaned at postnatal day 20 and maintained without additional intervention.  
An intraperitoneal glucose tolerance test (IPGTT) was performed as previously described 13 in 
the male offspring at 12 weeks of age. After 5 hours of fasting, baseline blood glucose levels 
were measured, followed by glucose injection (2g/kg, IP). Blood glucose was measured at 15, 
30, 60, and 90 minutes post-injection. The area under the curve (AUC) of the blood glucose 
curve was calculated for each mouse.  
Dams and male offspring (13 weeks old) were euthanized after deep anaesthesia (2% 
isoflurane). Livers were harvested, weighed and then either snap-frozen and stored at -80°C or 
fixed in 10% formalin for further analyses. Liver weights (%) were calculated as a fraction of 
body weight. Blood was collected via cardiac puncture and glucose levels were measured 
(Accu-Check(R), Roche, CA, USA). Plasma was separated and stored at -20°C for further 
analysis.  
Bioassays  
The plasma activity of Alanine Transaminase (ALT) was measured using the Alanine 
Transaminase Colorimetric Activity Assay Kit (Cayman Chemical, MI, USA) according to the 
manufacturer’s instructions. Plasma insulin concentration was measured by ELISA (Abnova, 
Taiwan) according to the manufacturer’s instructions. Liver lipids were extracted using the 
Folch method 14, as previously described 10. Plasma, liver extracts and glycerol standards 
(Sigma-Aldrich, MO, USA) were incubated with triacylglycerol reagent (Roche Diagnostics, 
Basel, Switzerland) using an in-house assay 13. Plasma non-esterified free fatty acid (NEFA) 
concentrations were measured using a NEFA kit (WAKO, Osaka, Japan). The insulin 
resistance index Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) was 
calculated as insulin (µU/mL) x glucose (mM)/22.5. 
Real-time (rt)-PCR 
Total mRNA was extracted from frozen liver tissue with TriZol reagent (Life Technologies, 
CA, USA) and the first-strand cDNA was generated using M-MLV Reverse Transcriptase, 
RNase H, Point Mutant Kit (Promega, WI, USA). Target gene expression was quantified with 
manufacturer pre-optimised and validated TaqMan primers and probes (See Table, 
Supplemental Digital Content 1, which shows details of the primers and probes used, Thermo 
Fisher, CA, USA) and standardised to 18s RNA. The probes of the target genes were labelled 
with FAM and those for housekeeping 18s RNA were labelled with VIC. The average of the 
Sham group was assigned the calibrator against which all other results were expressed as fold 
changes. 
Mitochondrial DNA copy number 
DNA was extracted from liver tissue using the DNeasy Blood and Tissue kit (Qiagen). The 
content of mtDNA was measured by quantifying mRNA expression of mitochondrial-encoded 
gene cytochrome c oxidase subunit 1 (COX1) (forward primers 5-ACTATACTACTACTAA-
CAGACCG-3, reverse primers 5-GGTTCTTTTTTTCCGGAGTA-3) against the nuclear-
encoded gene cyclophilin A (forward primers 5-ACACGCCATAATGGCACTGG-3, reverse 
primers 5-CAGTCTTGGCAGTGCAGAT-3), as we have previously published. COX1 gene 
expression was standardised to the housekeeping gene, cyclophilin A using ∆∆Ct method. The 
average of the Sham group was assigned the calibrator against which all other results were 
expressed as fold changes. 
Western Blotting 
After homogenisation of liver tissue, whole protein and mitochondrial protein samples were 
extracted via differential centrifugation, as previously described 15. Protein samples were 
separated on NuPage Novex 4-12% Bis-Tris gels (Life Technologies, CA, USA) and 
transferred to PVDF membranes (Pierce, IL, USA). After blocking with 5% skim milk, the 
membranes were incubated with primary antibodies of interest (mitophagy: microtubule-
associated 1A/1B light chain protein 3 ( LC3A/B II, 1:2000, Cat# 4108 S, Cell Signalling 
Technology, MA, USA), dominant optic atrophy (OPA-1, 1:2000, Cat# NB110-55290, Novus 
Biotechnology, CO, USA), dynamin-related protein 1 (DRP-1, Cat# NB110-55237, 1:2000, 
Novus Biotechnology, CO, USA); endogenous mitochondrial antioxidants: manganese 
superoxide dismutase (MnSOD, 1:2000, Cat# 06-984, Millipore, MA, USA), glutathione 
peroxidase 1 (GPx1, 1:250, Cat# AF3798, R&D Systems, MN, USA); insulin signalling: 
phosphorylated-protein kinase B (p-Akt (Thr308), Cat#9271, Cell Signalling Technology, MA, 
USA); lipid metabolism: fatty acid synthase (FASN, Cat# 3180 S, 1:2000, Cell Signalling 
Technology, MA, USA)), followed by the corresponding secondary antibody (Abcam, 
Cambridge, UK). Bands were detected with SuperSignal West Pico Chemiluminescent 
substrate (Thermo Fisher Scientific, CA, USA) and Fujifilm LAS-3000 (Fujifilm, Tokyo, 
Japan) and then quantified with ImageJ (National Institutes of Health, MD, USA). Results were 
expressed as a ratio against the housekeeping protein β-actin or cytochrome c oxidase subunit 
(COX) IV for mitochondrial proteins. 
Immunohistochemistry 
Formalin-fixed, paraffin-embedded livers were sectioned at 5µm. Sections were deparaffinised 
and rehydrated in xylene and decreasing grades of ethanol. Antigen retrieval was performed 16 
before the sections were incubated with the following anti-rabbit primary antibodies: 
nitrotyrosine (1:400, Cat# 06-284, Merck, NJ, USA), or F4/80 (1:300, Cat# ab111101, Abcam, 
Cambridge, UK) and visualised with the horseradish peroxidase anti-rabbit Envision system 
(Dako Cytochemistry, Tokyo, Japan). Sections were counterstained with haematoxylin and 
quantified with ImageJ (National Institutes of Health, MD, USA).   
Statistical Analysis 
Results are expressed as mean ± SEM and were analysed using one-way ANOVA with Fisher’s 
Least Significant post hoc test if the data were normally distributed. If the data were not 
normally distributed, they were log transformed to achieve normality of distribution before 




Metabolic markers  
In the dams, exposure to nicotine-containing e-vapour (E-cig18) did not alter body or liver 
weight. Blood glucose concentration was 23% higher in E-cig18 dams, but this was not 
significant (Table 1). The expression of the insulin-independent glucose transporter (Glut)2 
was not different among the groups (Figure 1a), whereas the expression of insulin-dependent 
Glut4 was increased in the E-cig18 dams (P<0.05 vs Sham, Figure 1b). There were no changes 
in the mRNA expression of markers for glycolysis and gluconeogenesis (phosphofructokinase 
(PFK)1 and forkhead box protein (FOX)O1 (Figure 1c,d)). Furthermore, there was no 
difference in plasma insulin levels among the groups (Table 1). However, HOMA-IR index, 
an indicator of insulin resistance, was increased in the E-cig18 dams (P<0.01 vs Sham, Table 
1), associated with a decrease in insulin signalling element, p-Akt (P<0.05 vs Sham, Figure 
1e). Liver and plasma triglyceride (TG) concentrations were not changed in E-cig18 dams 
(Table 1, Figure 1f). Thus, direct exposure to nicotine-containing e-vapour caused insulin 
resistance, but not increased hepatic glucose production.  
The dams exposed to nicotine-free e-vapour (E-cig0) were heavier than E-cig18 dams 
(P<0.05), with bigger liver sizes (P<0.05 vs Sham, Table 1) but not when expressed as a 
percentage of the body weight (Table 1). Glut4 expression was also increased in the E-cig0 
dams compared to the Sham dams (P<0.01, Figure 1b). In the E-cig0 dams, HOMA-IR index 
was increased (P<0.05 vs Sham, Table 1) which was also associated with a decrease in liver p-
Akt levels (P<0.05 vs Sham, Figure 1e). In addition, liver TG concentrations were increased in 
the E-cig0 dams (P<0.05 vs Sham, Figure 1f), along with increased plasma non-esterified fatty 
acid (NEFA) concentrations (P<0.05 vs Sham, Table 1). Hepatic FASN protein level was 
significantly increased in the E-cig0 dams (P<0.05 vs Sham, Figure 1g). Therefore, direct 
exposure to nicotine-free e-vapour also induced insulin resistance and impaired insulin receptor 
pathway activation. In addition, the increase in hepatic de-novo lipogenesis is linked to an 
increase in hepatic triglyceride and plasma NEFA concentrations.  
Markers of liver damage  
Plasma alanine aminotransferase (ALT) activity, a clinical marker of liver damage, was not 
changed in the E-cig18 dams (Table 1). In addition, the hepatic oxidative stress injury marker 
nitrotyrosine, mitochondrial antioxidants MnSOD and GPx1, and the pro-inflammatory 
cytokine TNF-α were not different between the E-cig18 dams and the Sham dams (Figure 2). 
Overall, exposure to nicotine-containing e-vapour did not result in any measurable liver 
damage in the dams.  
In contrast, plasma ALT activity was increased in the E-cig0 dams compared to the E-cig18 
dams (P<0.05, Table 1). Hepatic nitrotyrosine staining was increased in the E-cig0 dams 
compared to the Sham dams (P<0.05, Figure 2a). Furthermore, MnSOD expression was 
decreased in the E-cig0 dams (P<0.05 vs Sham, Figure 2b). The E-cig0 dams also had increased 
F4/80 positive cell number (P<0.05 vs Sham, Figure 2d) and increased mRNA expression of 
IL-1β in the liver (P<0.05 vs Sham, Figure 2f). Increased hepatocyte damage in the E-cig0 
dams was associated with decreased endogenous mitochondrial antioxidants suggesting 
increased oxidative stress, along with increased macrophage infiltration and inflammation.   
Liver mitochondrial markers 
In the E-cig18 dams, there were no changes in mtDNA copy number, mitochondrial fusion 
marker DRP-1, fission protein OPA-1, and mitochondrial biogenesis marker PGC1α compared 
to the Sham dams (Figure 3a-c,e). The hepatic protein level of autophagy marker (LC3A/B II) 
was decreased in the E-cig18 dams compared to the Sham dams (P<0.01, Figure 3d). Nicotine-
containing e-vapour exposure did not change liver mitochondrial number, mitophagy and 
mitochondrial biogenesis markers in the dams.  
In contrast, among E-cig0 dams the mtDNA copy number was decreased compared to the Sham 
dams (P<0.05, Figure 3a). DRP-1 protein levels were increased in the E-cig0 dams (P<0.01 vs 
E-cig18, Figure 3b). Meanwhile, LC3A/B II protein levels were increased in the E-cig0 dams 
compared to the E-cig18 dams but were not different from the Sham dams (P<0.01, Figure 3d). 
The expression of PGC1α was decreased in the E-cig0 dams compared to the Sham dams 
(P<0.05, Figure 3e). E-cig0 exposure resulted in hepatic mitochondrial damage as indicated by 
a reduction in mtDNA copy number, which could be due to reduced mitochondrial biogenesis 
and increased mitochondrial fission and subsequent recycling. These mitochondrial alterations 
could be responsible for the oxidative stress, inflammation, and liver damage that was 
observed.  
Offspring 
Metabolic markers  
Intrauterine exposure to nicotine-containing e-vapour did not alter liver or body weight in 13 
weeks old male offspring (Table 2). The area under the curve (AUC) for IPGTT was increased 
in the E-cig18 offspring (P<0.05 vs Sham offspring, Figure 4a). No changes in the blood 
glucose or plasma insulin levels were observed in E-cig18 offspring (Table 2). In addition, no 
differences in the glucose metabolic markers, Glut2, Glut4, and PFK1 were observed in the E-
cig18 offspring (Figure 4c-e). However, the expression of the gluconeogenesis marker, 
FOXO1, was increased in the E-cig18 offspring (P<0.05 vs Sham, Figure 4f), with a significant 
increase in p-Akt levels (P<0.05 vs Sham; P<0.01 vs E-cig0, Figure 4g). Liver TG 
concentrations were increased (P<0.01 vs Sham, Figure 4h), associated with an increase in 
FASN protein level (P<0.05 E-cig18 vs Sham, Figure 4i). Plasma TG and NEFA 
concentrations were not significantly changed in the E-cig18 offspring (Table 2). Thus, 
maternal exposure to nicotine-containing e-vapour caused glucose intolerance associated with 
impaired insulin signalling element and increased hepatic gluconeogenesis, as well as increased 
hepatic triglyceride accumulation associated with increased de-novo lipogenesis in the 
offspring.  
E-cig0 offspring had smaller liver weights compared to the Sham and E-cig18 offspring 
(P<0.05, Table 2). In addition, the IPGTT AUC value was increased in the E-cig0 offspring 
compared to the Sham offspring (P<0.05, Figure 4a). E-cig0 offspring also had increased 
mRNA expression of glucose transporters Glut2 (P<0.01 vs Sham and P<0.05 vs E-cig18, 
Figure 4b) and Glut4 (P<0.05 vs Sham, Figure 4c), glycolysis marker PFK1 (P<0.05 vs Sham 
and E-cig18, Figure 4d), and gluconeogenesis marker FOXO1 (P<0.01 vs Sham and P<0.05 vs 
E-cig18, Figure 4e). FASN protein expression was similar to the Sham offspring (P<0.01 vs 
E-cg18 offspring, Figure 4h). Maternal exposure to nicotine-free e-vapour led to glucose 
intolerance and altered levels of hepatic glucose metabolic makers in the offspring.  
Markers of liver damage  
MnSOD and Gpx1 levels were both decreased in the E-cig18 offspring, but without reaching 
statistical significance (Figure 5a,b). No changes were found in the markers of inflammation 
in the E-cig18 dams (Figure 5d-f). Thus, maternal exposure to nicotine-containing e-vapour 
did not cause measurable pathology in offspring’s liver.   
By contrast, in the E-cig0 offspring, there was an increase in nitrotyrosine staining in the liver 
(P<0.05 vs Sham and E-cig18, Figure 5a). This was associated with a decrease in the levels of 
the mitochondrial antioxidant GPx1 (P<0.01 vs Sham, Figure 5c). In addition, E-cig0 offspring 
had a 30% increase in mRNA expression of TNF-α compared to the Sham and a 46% increase 
compared to E-cig18 offspring (P<0.05, Figure 5d). No differences in IL-1β expression was 
observed (Figure 5e). Maternal exposure to nicotine-free e-vapour led to increased oxidative 
stress and inflammation in the offspring’s liver.  
Liver mitochondrial markers 
In E-cig18 offspring, there were no changes in mitochondrial number as assessed by mtDNA 
copy number, markers of mitophagy (OPA-1 and DRP-1), autophagy (LC3A/B II), and 
mitochondrial biogenesis (PGC1α, Figure 6). Thus, maternal exposure to nicotine-containing 
e-vapour did not affect liver mitochondrial health.   
In contrast, E-cig0 offspring had reduced numbers of mitochondria as assessed by mtDNA 
copy number compared to Sham offspring (P<0.05, Figure 6a). There was an increase in 
autophagy LC3A/B II levels compared to the Sham offspring (P<0.05, Figure 6d). There were 
no changes in mitophagy and mitochondrial biogenesis markers (Figure 6b,c,e). Therefore, 
maternal exposure to nicotine-free e-vapour may injure mitochondria resulting in increased 
autophagy in the E-cig0 offspring.  
Discussion 
The recent popularity of e-cigarette vaping among young people has affected women of 
reproductive age, increasing the incidence of intrauterine e-vapour exposure. Identifying the 
metabolic and hepatic consequences of long-term intrauterine e-vapour exposure is essential, 
to advise the pregnant women. Such risk information won’t be imminently available in humans. 
Nicotine-free e-vapour (E-cig0) was detrimental to liver health in both dams and male offspring 
by inducing oxidative stress, injury, and inflammation. Therefore, the chemicals from heated 
flavouring compounds and humectants could contribute to the adverse health impacts, where 
the level of nicotine adopted in this study seems to provide a partial protective effect in the 
offspring. However, exposure to nicotine-containing e-vapour (E-cig 18) still caused 
intrauterine underdevelopment and promoted hepatic steatosis in adult offspring. 
The use of flavouring compounds makes e-cigarettes enticing, resulting in continued use even 
in the absence of the addictive additive, nicotine. Many flavouring compounds (such as candy 
and chocolate) are especially appealing to younger individuals 4. As a result, some states in the 
US have proposed bans on flavoured e-cigarettes except tobacco flavour. Here we showed that 
nicotine-free, tobacco flavoured e-vapour still had significant health concerns, not only to the 
direct user but also their offspring, mostly attribute to heated humectants. Liver mitochondrial 
health was impaired in the E-cig0 dams, reflected by reduced mtDNA copy number and 
reduced mitochondrial antioxidants. Mitochondria are intracellular organelles responsible for 
nutrient metabolism and are also vulnerable to oxidative stress. Upon injury, mitophagy 
separates the injured fragments to be eliminated by autophagosomes (formed by LC3A/B), and 
combines healthy fragments via fusion to regenerate a new healthy mitochondrion. If the 
damaged mitochondria are not removed, inflammation and oxidative stress are induced 17. 
Reduced hepatic mtDNA copy number in the E-cig0 dams could be due to a decrease in 
mitochondrial biogenesis. Furthermore, mitochondrial antioxidants protect mitochondria from 
oxidative stress induced damage, which was also reduced, promoting further oxidative stress 
injury. As a result, plasma ALT activity, a marker of hepatocellular damage, was increased, 
along with inflammation and macrophage infiltration. The increase in hepatic TG accumulation 
could arise from increased glucose uptake and conversion to TG through de-novo lipogenesis.   
In the E-cig0 offspring, gluconeogenesis was increased, which is linked to impaired systemic 
glucose clearance during IPGTT, but this does not seem to be due to insulin resistance. Glucose 
transporters were also increased in the liver, associated with increased glycolysis. This may 
increase the mitochondrial burden, where glucose is metabolised to ATP. As a result, E-cig0 
offspring exhibited a reduction in mitochondria number, whereas the mitochondrial repair 
mechanism, mitophagy, failed to compensate. The reduced mtDNA number is also consistent 
in the E-cig0 dams and offspring, indicating that these effects may have been passed on from 
the mother. The resulting hepatic oxidative stress and inflammation were associated with 
increased glucose uptake, potentially causing glucose intolerance. Thus, exposure to nicotine-
free e-vapour promotes liver disorders and alters nutrient metabolism in both the dams and 
their offspring.  
On the other hand, there were no significant changes in liver markers of glucose and lipid 
metabolism, as well as inflammation and oxidative stress in both E-cig18 dams and offspring. 
While unphysiologically high doses of nicotine in animal models is associated with liver 
damage 18, not all these detrimental effects are observed in humans mostly due to lower nicotine 
exposure in smokers than laboratory animals 19. In fact, nicotine has anti-inflammatory 
properties at physiological doses 20 leading to mostly negative findings in nutrient metabolic 
markers in E-cig18 dams and offspring. Similarly, exposure to other flavoured e-vapours was 
shown to increase airway inflammation, but not when nicotine was also included 21. Therefore, 
it is likely that the humectants of the e-liquids are the most detrimental aspect of using e-
cigarettes. Thus, nicotine may prevent some of the adverse impacts of maternal e-vapour 
exposure, but this has yet to be confirmed in humans which may take decades to conclude.  
However, E-cig18 offspring still experienced intrauterine underdevelopment similar as those 
from tobacco cigarette smokers 6. This may be secondary to nicotine-induced uteroplacental 
blood vessel constriction and reduced intrauterine resources 22. Increased liver triglyceride 
accumulation in E-cig18 offspring was associated with an increase in gluconeogenesis and de-
novo lipogenesis. Fatty liver is common in low birth weight infants 23 due to increased de-novo 
lipogenesis 24. Furthermore, glucose intolerance could be attributed to increased 
gluconeogenesis rather than insulin resistance 25.  
We need to acknowledge one limitation of this study by only investigating one dose of nicotine 
exposure. While the dose response effects of maternal e-vaping on offspring’s health outcome 
are unknown in humans, in tobacco cigarette smokers, there is a positive correlation between 
the daily cigarette number and the risk of miscarriage. Future studies can shed light on this 
aspect of e-cigarette users. 
In conclusion, direct and in-utero e-vapour exposure can lead to hepatic, lipid, and glucose 
metabolic disorders. The dose used in this study was low (equivalent to light smokers) and 
future studies can examine higher doses of e-vapour or nicotine. Overall, pregnant women 
should avoid the use of e-cigarettes, regardless of nicotine concentration, to reduce the risk of 
hepatic and metabolic disorders.   
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Figure 1. Hepatic mRNA expression of glucose metabolic (Glut2 (a), Glut4 (b), PFK1 (c), 
FOXO1 (d)), hepatic protein markers of insulin signalling (p-Akt (e)) and lipid synthesis 
(FASN (g)) and hepatic triglyceride levels (f). Results are expressed as Mean ± SEM (n=6). 
*P<0.05, **P<0.01 vs Sham. Data were analysed by one-way ANOVA with Fishers LSD post-
hoc test. E-cig0: nicotine-free e-vapour, E-cig18: nicotine-containing e-vapour, FASN: Fatty 
Acid Synthase, FOXO1: Forkhead box protein O1, Glut: Glucose transporter, NEFA: non-
esterified fatty acid, PFK: Phosphofructokinase, TG: triglyceride. 
Figure 2. Markers of oxidative stress (nitrotyrosine (a)), mitochondrial antioxidants (MnSOD 
(b), Gpx1 (d)) and inflammation (F4/80 (d), TNF-α (e), IL-1β (f)) in the Dams. Results are 
expressed as Mean ± SEM (n=5-8). *P<0.05 vs Sham. Data were analysed by one-way 
ANOVA with Fishers LSD post-hoc test. E-cig0: nicotine-free e-vapour, E-cig18: nicotine-
containing e-vapour, F4/80: EGF-like module-containing mucin-like hormone receptor-like 1, 
GPx1: glutathione peroxidase 1, IL-1β: Interleukin 1 beta, MnSOD: manganese superoxide 
dismutase, TNF-α: Tumor necrosis factor-α. 
Figure 3. Liver mitochondrial DNA copy number (a), markers of mitophagy (DRP-1 (b), OPA-
1 (c)), autophagy (LC3A/B II (d)), and mitochondrial biogenesis (PGC1α (e)) in the dams. 
Results are expressed as Mean ± SEM (n=5-8). *P<0.05, **P<0.01 vs Sham, ##P<0.01 vs E-
cig18. Data were analysed by one-way ANOVA with Fishers LSD post-hoc test. E-cig0: 
nicotine-free e-vapour, E-cig18: nicotine-containing e-vapour, DRP-1: Dynamin related 
protein 1, LC3A/B II: Microtubule associated 1A/1B light chain protein 3, OPA-1: 
Mitochondrial dynamin like GTPase, PGC-1α: Peroxisome proliferator-activated receptor 
gamma coactivator 1-α. 
 
 
Figure 4. IPGTT (a) and area under the curve (b, AUC) along with hepatic mRNA expression 
of glucose metabolic markers (Glut2 (c), Glut4 (d), PFK1 (e), FOXO1 (f)) along with insulin 
signalling (p-Akt (g)), liver TG (h) and lipid metabolic markers (FASN (i)) in the male 
offspring. Results are expressed as Mean ± SEM (n=6). *P<0.05, **P<0.01 vs Sham, #P<0.05, 
##P<0.01 vs E-cig18. Data were analysed by one-way ANOVA with Fishers LSD post-hoc 
test. AUC: area under the curve, E-cig0: nicotine-free e-vapour, E-cig18: nicotine-containing 
e-vapour, FASN: Fatty Acid Synthase, FOXO1: Forkhead box protein O1, Glut: Glucose 
transporter, IPGTT: intraperitoneal glucose tolerance test, PFK: Phosphofructokinase, TG: 
triglyceride.  
Figure 5. Markers of oxidative stress (nitrotyrosine (a)), mitochondrial antioxidants (MnSOD 
(b), Gpx1 (d)) and inflammation (F4/80 (d), TNF-α (e), IL-1β (f)) in the male offspring. Results 
are expressed as Mean ± SEM (n=5-8). *P<0.05, **P<0.01 vs Sham, # P<0.05 vs E-cig18. 
Data were analysed by one-way ANOVA with Fishers LSD post-hoc test. E-cig0: nicotine-free 
e-vapour, E-cig18: nicotine-containing e-vapour, F4/80: EGF-like module-containing mucin-
like hormone receptor-like 1, GPx1: glutathione peroxidase 1, IL-1β: Interleukin 1 beta, 
MnSOD: manganese superoxide dismutase, TNF-α: Tumor necrosis factor-α. 
Figure 6. Liver mitochondrial DNA copy number (a), markers of mitophagy (DRP-1 (b), OPA-
1 (c)), autophagy (LC3A/B II (d)), and mitochondrial biogenesis (PGC1α (e)) and in the male 
offspring. Results are expressed as Mean ± SEM (n=5-8). *P<0.05 vs Sham. Data were 
analysed by one-way ANOVA with Fishers LSD post-hoc test. E-cig0: nicotine-free e-vapour, 
E-cig18: nicotine-containing e-vapour, DRP-1: Dynamin related protein 1, LC3A/B II: 
Microtubule associated 1A/1B light chain protein 3, OPA-1: Mitochondrial dynamin like 
GTPase, PGC-1α: Peroxisome proliferator-activated receptor gamma coactivator 1-α. 
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Table 1. Parameters of the dams  
 Sham E-cig18 E-cig0 
Body weight (g) 26.1±0.38 25.6±0.89 27.8±0.34# 
Liver weight (g) 1.55 ± 0.07 1.73 ± 0.12 1.87 ± 0.10* 
Liver weight (%) 5.93±0.22 6.69±0.28 6.74±0.37 
Blood glucose (mM) 9.42 ± 0.83 11.6 ±0.87 10.6 ±0.46 
Plasma insulin (ng/mL) 0.70 ±0.047 0.89 ± 0.136 0.85 ± 0.089 
HOMA-IR index 6.5±0.620 11.3±1.20** 9.7±0.73* 
Liver TG (mg/g liver) 4.0±0.57 3.8±0.67 4.0±0.80 
Plasma NEFA (mEq/L) 2.1 ± 0.28 2.82 ± 0.23 3.67 ± 0.29* 
Plasma TG (mg/mL) 1.22±0.21 0.92±0.14 1.21±0.29 
Plasma ALT (U/L) 13.3±2.6 7.49±1.7 19.3±2.9# 
Results are expressed as Mean ± SEM. *P<0.05, **P<0.01 vs Sham, # P<0.05 vs E-cig18. Data 
were analysed by one-way ANOVA with Fishers LSD post-hoc test. ALT: Alanine 
transaminase, E-cig0: nicotine-free e-vapour, E-cig18: nicotine-containing e-vapour, NEFA: 
non-esterified fatty acid, TG: triglyceride.  
 
Table 1
Table 2. Parameters in the male offspring (13 weeks old) 
 Sham E-cig18 E-cig0 
Body weight (g) 26.5±0.52 26.01±0.32 26.02±0.33 
Liver weight (g) 1.33±0.05 1.31±0.03 1.18±0.02*# 
Liver weight (%) 4.99±0.12 5.02±0.09 4.54±0.09*# 
Plasma insulin (ng/mL) 0.50±0.015 0.51±0.026 0.56±0.018 
Plasma TG (mg/mL) 1.41±0.11 1.13±0.14 1.13±0.04 
Plasma NEFA (mEq/L) 4.13±0.47 3.54±0.62 4.20±0.34 
Plasma ALT (U/L) 23.0±0.8 24.7±2.9 25.8±2.5 
Results are expressed as Mean ± SEM. *P<0.05, **P<0.01 vs Sham, # P<0.05 vs E-cig18. Data 
were analysed by one-way ANOVA with Fishers LSD post-hoc test. ALT: Alanine 
transaminase, E-cig0: nicotine-free e-vapour, E-cig18: nicotine-containing e-vapour, NEFA: 
non-esterified fatty acids, TG: triglyceride. 
 
Table 2
Table, Supplemental Digital Content 1. TaqMan Probe sequence (Life Technologies, CA, 
USA) used for rt-PCR. 
Gene NCBI references Probe Sequence ID 
FOXO1 NM_019739.3 TCGGCGGGCTGGAAGAATTCAATTC Mm00490671_m1 
IL1B NM_008361.3 TCCTTGTGCAAGTGTCTGAAGCAGC Mm01336189_m1 
PFK1 NM_008826.4 GCGGTGATGCGCAAGGTATGAATGC Mm00435587_m1 
PGC1a NR_027710.1 CTGGAACTGCAGGCCTAACTCCTCC Mm01208835_m1 
SLC2A2 NM_031197.2 CCGCCTCCCCCGGCGCGCACACACC Mm00446229_m1 
SLC2A4 NM_009204.2 TGGCTCTGCTGCTGCTGGAACGGGT Mm00436615_m1 
TNFα  NM_013693.2  CCCTCACACTCAGATCATCTTCTCA  Mm00443259_g1  
Foxo1: Forkhead box protein O1, PFK1: Phosphofructokinase 1, Pgc1a:  Peroxisome 
proliferator-activated receptor gamma coactivator 1-α, slc2a2: Glut2, Slc2a4: Glut4, Tnfα: 
Tumor necrosis factor-α.  
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